scFv(CD33)-CD3zeta CAR-T Lentivirus

Chimeric antigen receptor T cell (CAR-T) therapy is a groundbreaking advancement in immunotherapy, particularly in the treatment of various hematological malignancies. CAR-T therapy genetically modifies a patient''s T cells to express a specific chimeric antigen receptor, enabling them to more effectively recognize and attack cancer cells. The process begins by isolating T cells from the patient''s blood, then activating, genetically modifying, and expanding them in the laboratory. A key component of CAR-T technology is the use of a lentiviral vector to deliver the genetic material encoding the CAR into the T cells. Lentiviruses offer the advantage of integrating into the host genome, enabling stable and sustained expression of the CAR. This approach not only enhances the specificity and potency of T cells against tumor antigens but also helps achieve long-term clinical responses and remissions.

The scFv(CD33)-CD3zeta CAR-T lentivirus represents a novel application of CAR-T therapy, targeting CD33, a common surface antigen in myeloid malignancies such as acute myeloid leukemia (AML). This CAR-T vector is designed to contain a single-chain variable fragment (scFv) derived from an antibody that specifically recognizes the CD33 antigen. This scFv serves as the binding domain, enabling CAR-T cells to recognize and bind to CD33-expressing cancer cells. The inclusion of the CD3zeta signaling domain is crucial, as it activates T cells upon antigen recognition, thereby enhancing T cell activation, proliferation, and cytotoxic activity against target cells. The scFv(CD33)-CD3zeta CAR-T lentivirus is engineered to generate a robust T cell response against CD33-positive malignancies.